Drug Profile
Research programme: infectious disease vaccines - Marker Therapeutics Inc
Alternative Names: Smallpox vaccine - Marker Therapeutics Inc; TPIV-300; TPIV-301Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator TapImmune
- Developer Marker Therapeutics Inc; Mayo Clinic
- Class Vaccines; Viral vaccines
- Mechanism of Action Major histocompatibility complex modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Smallpox; Viral infections
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Smallpox(Adjuvant therapy) in USA
- 28 Apr 2021 No recent reports of development identified for preclinical development in Viral-infections(Adjuvant therapy) in USA
- 15 Mar 2019 Preclinical development for viral infections and small pox vaccines is still ongoing in the US